Table 1 General characteristics of the whole population and according to statins use.
Whole population | Non-statin users | Statin users | p value | |
|---|---|---|---|---|
(N = 305) | (N = 242) | (N = 63) | ||
Age, years | 68.1 ± 10.3 | 66.8 ± 10.7 | 74.0 (54–86) | < 0.01 |
Males n, % | 251, 82 | 191, 78.9 | 60, 95.2 | < 0.01 |
BMI, kg/m2 | 25.8 ± 4.6 | 25.5 ± 4.7 | 26.0 (18.1–37.6) | 0.01 |
Cirrhosis n, % | 229, 75 | 185, 76.4 | 44, 69.8 | 0.28 |
HBV n, % | 47, 15 | 39, 16.1 | 8, 12.7 | 0.50 |
HCV n, % | 133, 44 | 119, 49.1 | 14, 22.2 | < 0.01 |
ALD n, % | 71, 23 | 57, 23.5 | 14, 22.2 | 0.82 |
MASLD n, % | 86, 28 | 56, 23.1 | 30, 47.6 | < 0.01 |
MetALD n, % | 24, 8 | 19, 7.8 | 5, 7.9 | 0.98 |
Hypertension n, % | 183, 60 | 135, 55.8 | 48, 76.2 | < 0.01 |
T2DM n, % | 97, 32 | 67, 27.7 | 30, 47.6 | < 0.01 |
Oesophagus varices n, % | 85, 27.9 | 70, 28.9 | 15, 23.8 | 0.72 |
Ascites n, % | 25, 8.2 | 22, 9.1 | 3, 4.7 | 0.51 |
HE n, % | 3, 1.0 | 3, 1.2 | 0, 0 | 0.91 |
Previous decompensation n, % | 21, 6.9 | 19, 7.9 | 2, 3.2 | 0.34 |
NBBS n, % | 72, 24 | 60, 24.8 | 12, 19.0 | 0.22 |
Number of nodules n, % | 0.49 | |||
1 | 52, 17 | 43, 17.8 | 9, 14 | |
2 | 35, 11.4 | 24, 9.9 | 11, 17.5 | |
3 | 32, 10.5 | 28, 11.6 | 4, 6.3 | |
> 3 | 186, 61 | 147, 60.7 | 39, 61.9 | |
MTD, mm | 45 (23–70.5) | 45 (22.5–72.5) | 41 (27.5–65.75) | 0.55 |
PVT n, % | 96, 31 | 76, 31.4 | 20, 31.7 | 0.96 |
Metastasis n, % | 114, 37 | 89, 36.8 | 25, 39.7 | 0.67 |
Hb, g/dl | 13.0 (12.0–14.3) | 13.0 (12.0–14.3) | 13.1 (11.9–14.9) | 0.88 |
PLT, mm3 | 145 (76–223) | 141 (76–222) | 151 (74–236) | 0.71 |
Bilirubin, mg/dl | 0.8 (0.56–1.30) | 0.84 (0.54–1.31) | 0.79 (0.57–1.23) | 0.71 |
Albumin, g/l | 3.90(3.60–4.20) | 3.90 (3.60–4.209 | 4.10 (3.80–4.30) | 0.02 |
Creatinine, mg/dl | 0.88 (0.74–1.12) | 0.84 (0.73–1.00) | 0.97 (0.76–1.30) | 0.01 |
AFP ng/ml | 16.5 (4.84–312) | 16 (5–320) | 19.6 (5.2–311) | 0.61 |
Best response | 0.47 | |||
SD n, % | 149, 48.9 | 12, 16.1 | 29, 46 | |
PR n, % | 69, 22.6 | 54, 22.3 | 15, 23.8 | |
CR n, % | 10, 3.3 | 6, 2.5 | 4, 6.3 | |
PD n, % | 77, 25.2 | 62, 25.6 | 15, 23.8 | |
Treatment time, months | 6.4 (2.7–13.3) | 6.3 (2.6–13.2) | 6.5 (3.1–14.5) | 0.62 |
Radiological progression n, % | 150, 49 | 122, 50.4 | 28, 44.4 | 0.57 |
Time to radiological progression, months | 6 (2.5–14) | 6 (2–14) | 7 (3–15) | 0.7 |
Treatment discontinuation n, % | 206, 67.8 | 169, 70 | 36, 57.1 | 0.12 |
Cause of treatment discontinuation: | 0.41 | |||
Clinician’s decision n, % | 18, 5.9 | 12, 5 | 6, 9.5 | |
Adverse events n, % | 32, 10.5 | 29, 12 | 2, 3.2 | |
Liver related events n, % | 18, 5.9 | 14, 5.8 | 4, 6.3 | |
Progression n, % | 128, 41.8 | 105, 43.4 | 23, 36.5 | |
Death n, % | 9, 2.6 | 8, 3.3 | 1, 1.6 | |
Death n, % | 142, 46.7 | 121, 50 | 21, 33.3 | 0.02 refers to death |
Liver related mortality n, % | 12, 3.9 | 11, 4.5 | 1, 1.6 | 0.47 refers to liver related mortality |
Tumour progression n, % | 111, 36.3 | 95, 39.4 | 16, 25.4 | 0.06 refers to tumour progression |
